Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
The product is expected to be launched in December 2023
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)